TORONTO, CANADA [November 12, 2024] – Allergan Aesthetics proudly announces the Health Canada approval of CoolSculpting® ELITE, the next evolution in body contouring.
CoolSculpting® ELITE is the next generation cryolipolysis device. Featuring two detachable applicator heads supported by a powerful chiller enabling a more efficient treatment process, a sleek, sophisticated redesign and modernized user interface, and many more technology upgrades, every detail adds up to an unparalleled, elite experience.
“The launch of CoolSculpting® ELITE in Canada embodies our relentless commitment to innovation and optimal patient outcomes” said Carolina Martin, General Manager, Allergan Aesthetics Canada. “As the creator of the body contouring category, we’re proud to lead ahead of the curve and offer knowledge and tools to deliver exceptional results for both practices and patients across the country.”
CoolSculpting® ELITE has been engineered for faster, improved results, featuring newly designed, detachable applicators that offer better contour to the body’s natural curves for enhanced fit and comfort. This two-in-one game-changing innovation enhances clinic efficiency, reducing the time patients spend in the chair.
Prioritizing patient safety, CoolSculpting® ELITE has an established safety profile with patented safety measures. The system includes patented Freeze Detect® sensors that monitor tissue during treatment and stop the process if a freeze condition is detected. Real-time CoolControl™ sensors adjust the cooling power to optimize patient outcomes, while a patented Gel Pad provides consistent thermal contact between the applicator and skin, further protecting the patient’s skin.
4.1 million people in Canada are considering non-invasive fat reduction treatments like CoolSculpting®1 and CoolSculpting® is the pioneer of the body contouring category, with over 20+ years of research2 and 17+ million treatment cycles worldwide.3 NEW CoolSculpting® ELITE builds on this heritage with next-generation technology that delivers on results.
COOLSCULPTING® ELITE IMPORTANT SAFETY INFORMATION
Important Safety Information
During the procedure patients may experience sensations of pulling, tugging, mild pinching, intense cold, tingling, stinging, aching, cramping and discomfort at the treatment site. These sensations subside as the area becomes numb. Following the procedure, typical side effects include redness, firmness, transient blanching and/or mild bruising around the edges of the treatment area, tingling, stinging, skin inflammation, throat discomfort after submental treatment, redness and mild to moderate bruising (in rare instances can be severe), swelling, tenderness, cramping, aching, itching, skin sensitivity and numbness. Numbness can persist for up to several weeks. A sensation of fullness in the back of the throat may occur after submental treatment.
The CoolSculpting® ELITE procedure is not a treatment for obesity. CoolSculpting® ELITE is not a weight loss procedure and should not replace a healthy diet and active lifestyle.
The suitability of CoolSculpting® ELITE treatment on an individual patient basis should always be considered as part of the assessment and consultation process. CoolSculpting® ELITE is not suitable for all patients. Please consult the ‘Directions for use’ prior to the procedure. Patient results may vary.
For a complete list of Contraindications, Warnings, Precautions, and Potential Side Effects, consult the CoolSculpting® ELITE System User Manual. Treatment applications that deviate from the guidelines are not recommended.
Adverse events should be reported to Allergan Aesthetics, an AbbVie company at 1-866-653-9308.
©2024 AbbVie. All rights reserved.
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.ca or follow us on Instagram at @allerganaestheticsCA.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2022 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Contacts
Allergan Aesthetics
MR-Canada_Communications@Allergan.com
Holly Thornton
Proof Strategies
1 Power BI Dashboard – Allergan Aesthetics. Consumer Funnel Dashboard from International Market Research – Allergan Aesthetics, Power BI
2 Allergan Inc. Unpublished data. CoolSculpting® science and evolution: Nearly 20 years of research and development. INT/0586/2018. May 2018.
3 Allergan Inc. Unpublished Data. Data on file - CoolSculpting® - 17 million treatment cycles. REF-112195. June 2023.